Molecular biology of human immunodeficiency virus type-1

Transfusion Science

Volumn 17, Issue 3, 1996, Pages 351-378

  Joshi, Sadhna ^a   Joshi, Rajiv L ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; VIROGENESIS; VIRUS PATHOGENESIS;

EID: 0347770330     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-3886(96)00004-5     Document Type: Article

References (314)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet D, Axler-Blin C: Isolation of T-lymphotropic retrovirus from a patient at risk for AIDS. Science 1983; 220:868-871.
2. Steffy K, Wong-Staal F: Genetic regulation of HIV. Microbiol Rev 1991; 55:193-205.
3. Haseltine WA: Molecular biology of HIV-1. FASEB J 1991; 5:2349-2360.
4. Poeschla E, Wong-Staal F: Molecular biology of HIV: challenges for the second decade. AIDS Res Hum Retroviruses 1994; 10:111-112.
5. Subbramanian RA., Cohen EA: Molecular biology of the HIV accessory proteins. J Virol 1994; 68:6831-6835.
6. Cullen BR: RNA-sequence-mediated gene regulation in HIV-1. Infectious Agents and Disease 1994; 3:68-76.
7. Trono D: HIV accessory proteins: leading roles for the supporting cast. Cell 1995; 82:189-192.
8. + individuals. Virology 1995; 206:196- 202.
9. Aloia RC, Jensen FC, Curtain CC, Mobley PW, Cordon LM: Lipid composition and fluidity of the HIV. Proc Natl Acad Sci USA 1988; 85:900-904.
10. Gelderblom HR: Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 1991; 5:617-638.
11. Chatterjee S, Basak S, Khan NC: Morphogenesis of HIV-1. Pathobiology 1992; 60:181-186.
12. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD: Biosynthesis, cleavage and degradation of the HIV-1 Env glycoprotein gp160. Proc Natl Acad Sci USA 1988; 85:9580-9584.
13. Mervis RJ, Ahmad A, Lillehoj EP, Raum MG, Salazar FHR, Chan HW, Venkatesan S: The gag gene products of HIV-1: alignment within the gag open reading frame, identification of post-translational modifications, and evidence for alternative Gag precursors. J Virol 1988; 62:3993-4002.
14. Gelderblom HR, Hausmann EHS, Ozel M, Pauli G, Koch MA: Fine structure of HIV and immunolocalization of structural proteins. Virology 1987; 156:171-176.
15. Liu, H, Wu X, Newman M, Shaw GM, Hahn BH, Kappes JC: The Vif protein of HIV-1 and SIV in packaged into virions and associates with viral core structures. J Virol 1995; 69:7630-7638.
16. Cohen EA, Dehni G, Sodroski JG, Haseltine WA: HIV vpr product is a virion-associated regulatory protein. J Virol 1990; 64:3097-3099.
17. McDougal JS, Klatzmann DR, Maddon PJ: CD4-gp120 interactions. Curr Opin Immunol 1991; 3:552-558.
18. Rosenberg ZF, Fauci AS: Immunopathogenesis of HIV infection. FASEB J 1991; 5:2382-2390.
19. Dalgleish AG, Beverly PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763-767.
20. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312:767-768.
21. + T cells by a complex of the 110K viral protein and the T4 molecule. Science 1988; 331:382-385.
22. Harrington RD, Geballe AP: Cofactor requirement for HIV-1 entry into a CD4 expressing human cell line. J Virol 1993; 67:5939-5947.
23. + cells via virus envelope fusion to the plasma membrane. Cell 1987; 49:659-668.
24. McClure MO, Marsh M, Weiss RA: (1988). HIV infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J 1988; 7:513-518.
25. + T lymphocytes. J Virol 1992; 66:6489-6495.
26. St. Lucy S, Arts E, Geleziunas R, Bour S, Wainberg MA: Infection of human monocyte-derived macrophages by HIV mediated by cell-to-cell transmission. J Med Virol 1993; 41:71-78.
27. Takeda A, Tuazon CU, Ennis FA: Antibody enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242:580-583.
28. + and Fc gamma R. J Virol 1990; 64:5605-5610.
29. Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD: Complement mediates HIV-1 infection of a human T cell line in a CD4 and antibody independent fashion. J Exp Med 1991; 173:1151-1158.
30. Spector DH, Wade E, Wright DA, Koval V, Clark C, Jaquish D, Spector SA: HIV pseudotypes with expanded cellular and species tropism. J Virol 1990; 64:2298-2308.
31. Le Guern M, Levy JA: HIV-1 can superinfect HIV-2-infected cells: pseudotype virions produced with expanded cellular host range. Proc Natl Acad Sci USA 1992; 89:363-367.
32. Kim S, Ikeuchi K, Groopman J, Baltimore D: Factors affecting cellular tropism of HIV. J Virol 1990; 64:5600-5604.
33. Bergeron L, Sullivan N, Sodroski J: Target cell-specific determinants of membrane fusion within the HIV-1 gp120 third variable region and gp41 amino terminus. J Virol 1992; 66:2389-2397.
34. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR: Identification of the Env V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253:71-74.
35. Cann AJ, Churcher MJ, Boyd M, O'Brien W, Zhao JQ, Zack J, Chen ISY: The region of the env gene of HIV-1 responsible for determination of cell tropism. J Virol 1992; 66:305-309.
36. Sharpless NE, O'Brien WA, Verdin E, Kufta CV, Chen ISY, Dubois-Dalcq M: HIV-1 tropism for brain microglial cells is determined by a region of the Env glycoprotein that also controls macrophage tropism. J Virol 1992; 66:2588-2593.
37. Dewhurst S, Sakai K, Bresser J, Stevenson M, Evinger-Hodges M, Volsky DJ: Persistent productive infection of human glial cells by HIV and by infectious molecular clones of HIV. J Virol 1989; 61:3774-3782.
38. Fantini J, Yahi N, Baghdiguian S, Chermann J: Human colon epithelial cells productively infected with HIV show impaired differentiation and altered secretion. J Virol 1992; 66:5800-585.
39. Phillips DM, Bourinbaiar AS: Mechanism of HIV spread from lymphocytes to epithelia. Virology 1992; 186:261-273.
40. Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F: Inhibition of entry of HIV-1 in neural cell lines by antibodies against GalCer. Science 1991; 253:320-323.
41. Cook DG, Fantini J, Spitalnik SL, Gonzalez-Scarano F: Binding of HIV-1 gp120 to GalCer: relationship to the V3 loop. Virology 1994; 201:206-214.
42. Moses AV, Bllom FE, Pauza CD, Nelson JA: HIV infection of human brain capillary endothelial cells occurs via a CD4/ GalCer-independent mechanism. Proc Natl Acad Sci USA 1993; 90:10474-10478.
43. Clapham PR, Weber JN, Whitby D, McIntosh K, Dalgleish AG, Maddon PJ, Deen KC, Sweet RW, Weiss RA: Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989; 337:368-370.
44. - human fibroblastoid cells. Proc Natl Acad Sci USA 1989; 86:4287-4290.
45. agm. AIDS 1990; 4:537-544.
46. Gilboa E, Mitra SW, Goff S, Baltimore D: A detailed model of reverse transcription and tests of crucial aspects. Cell 1990; 18:93-100.
47. Panganiban AT, Fiore D: Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science 1988; 241:1064-1069.
48. Goff SP, Retroviral RT: syntheses, structure and function. J AIDS 1990; 3:817-831.
49. Lys: role of RT. TIBS 1994; 19:114-118.
50. + cells. FEBS Lett 1994; 341:49-53.
51. Chameau P, Alizon M, Clavel F: A second origin of DNA plus-strand synthesis is required for optimal HIV replication. J Virol 1992; 66:2814-2820.
52. Chameau P, Mirambeau G, Roux P, Paulous S, Bue H, Clavel F: HIV-1 reverse transcription. A termination step at the centre of the genome. J Mol Biol 1994; 241:651-662.
53. Famet CM, Haseltine WA: Determination of viral proteins present in HIV-1 preintegration complex. J Virol 1991; 65:1910-1915.
54. Lewis P, Gensel M, Emerman M: HIV infection of cells arrested in the cell cycle. EMBO J 1992; 11:3053-3058.
55. Stevenson M, Bukrinsky M, Haggerty S: HIV-1 replication and potential targets for intervention. AIDS Res Hum Retroviruses 1992; 8:107-117.
56. Bkrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M: Association of IN, MA and RT antigens of HIV-1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993; 90:6125-6129.
57. Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman H, Ratner L, Stevenson M, Emerman M: The Vpr protein of HIV-1 influences nuclear localization of viral nucleic acids in non-dividing host cells. Proc Natl Acad Sci USA 1994; 91:7311-7315.
58. Fujiwara T, Mizuuchi K: Retroviral DNA integration: structure of an integration intermediate. Cell 1988; 54:497-504
59. Varmus H: Retroviruses. Science 1988; 240:1427-1435.
60. LaFemina RL, Callahan PL, Cordingley MG: Substrate specificity of recombinant HIV in protein. J Virol 1991; 65:5624-30.
61. Kulkosky J, Skalka AM: HIV DNA integration: observations and inferences. J AIDS 1990; 3:839-851.
62. Bushman FD, Craigie R: Activities of HIV integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA 1991; 88:1339-1343.
63. Engelman A, Mizuuchi K, Craigie R: HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67:1211-1221.
64. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cells activation and proviral integration. EMBO J 1990; 9:1551-1560.
65. Chen BK, Saksela K, Andino R, Baltimore D: Distinct modes of HIV-1 proviral latency revealed by superinfection of non-productive infected cell lines with recombinant luciferase-encoding viruses. J Virol 1994; 68:654-660.
66. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC: Activation of HIV-1 LTR by T cell mitogens and the trans-activator protein of HIV-1. Science 1987: 238:1575-1578.
67. Valerie K, Delers A, Bruck C, Thiriart C, Rosenberg H, Debouck C, Rosenberg M: Activation of HIV-1 by DNA damage in human cells. Nature 1988; 333:78-81.
68. Bohnlein E, Siekevitz M, Ballard D W, Lowenthal JW, Rimsky L, Bogerd H, Hoffman J, Wano Y, Franza BR, Greene WC: Stimulation of HIV-1 enhancer by the HTLV-1 tax gene product involved in the action of inducible cellular proteins, J Virol 1989; 63:1578-1586.
69. Laspia MF, Rice AP, Mathews MB: Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. Genes Dev 1990; 4:2397-2408.
70. Gendelman HE, Phelps W, Feigenbaum L, Ostove JM, Adachi A, Howley PM, Khoury G, Ginsberg HS, Martin MA: Trans-activation of the HIV LTR sequence by DNA viruses. Proc Natl Acad Sci USA 1986; 83:9759-9763.
71. + T lymphocytes by HIV-1 and HHV-6. Nature 1989; 337:370-373.
72. Reinberg D, Horikoshi M, Roeder RG: Factors involved in specific transcription in mammalian RNA polymerase II. Functional analysis of initiation factors IIA and IID and identification of a new factor operating at sequences downstream of the initiation site. J Biol Chem 1987; 262:3322-3330.
73. Cullen BR: Regulation of HIV-1 gene expression. FASEB J 1991; 5:2361-2368.
74. Rosen CA, Sodroski JG, Haseltine WA: The location of cis-acting regulatory sequences in the HTLVIII/LAVLTR. Cell 1985; 41:813-823.
75. Ratner L, Haseltine WA, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313:277-284.
76. Proudfoot N: Poly(A)signals. Cell 1991; 64:671-674.
77. Valsamakis A, Zeichner S, Carswell S, Alwine JC: The HIV-1 polyadenylation signal: a 3′ long terminal repeat element upstream of the AAUAAA necessary for efficient polyadenylation. Proc Natl Acad Sci USA 1991; 88:2108-2112.
78. Weichs an der Glon WC, Monks J, Proudfoot NJ: Occlusion of the HIV poly(A) site. Genes Dev 1991; 5:244-253.
79. Lu Y, Stenzel M, Sodroski JG, Haseltine W A: Effects of LTR mutations on HIV-1 replication. J Virol 1989; 63:4115-4119.
80. Lu Y, Hey A, Touzjian N, Stenzel M, Haseltine WA: Cellular transcription factors which regulate HIV-1 replication, in Haseltine WA & Wong-Staal F, (eds): Genetic Structure and Regulation of HIV. New York, Raven Press, 1991.
81. Gaynor R: Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 1992; 6:347-363.
82. Lu Y, Touzjian N, Stenzel M, Dorfman T, Sodroski JG, Haseltine WA: Identification of CRSs within the negative regulatory element of HIV-1. J Virol 1990; 64:5226-5229.
83. Greenblatt I: Roles of TFIID in transcription initiation by RNA polymerase II. Cell 1991; 66:1067-1070.
84. Jones KA, Kadonaga JT, Luciw PA, Tjian R: Activation of AIDS retrovirus promoter by the cellular transcriptional factor Sp1. Science 1986; 232:755-759.
85. Garcia JA, Wu FK, Mitsuyasu R, Gaynor RB: Interactions of cellular proteins involved in the transcriptional regulation of HIV. EMBO J 1987; 6:3761-3770.
86. Wu FK, Garcia JA, Harrich D, Gaynor RB: Purification of the HIV-1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J 1988; 7:2117-2129.
87. Kawakami C, Scheidereit C, Roeder RG: Identification and purification of human immunoglobulin-enhancer-binding proteins (NF-κB) that activates from HIV-1 promoter in vitro. Proc Natl Acad Sci USA 1988; 85:4700-4704.
88. Kamine J, Chinnadurai G: Synergistic activation of the HIV-1 promoter by the viral Tat protein and cellular transcription factor Sp1. J Virol 1992; 66:3932-3936.
89. Liu J, Perkins ND, Schmid RM, Nabel GJ: Specific NF-κB subunits act in concert with Tat to stimulate HIV-1 transcription. J Virol 1992; 66:3883-3887.
90. Newman M, Harrison J, Saltavelli M, Hedjiyannis E, Erfle V, Felber BK, Pavlakis G: Splicing variability in HIV-1 revealed by quantitative RNA polymerase chain reaction. AIDS Res Human Retroviruses 1994; 10:1531-1542.
91. Allan JA, Coligan JE, Lee TH, McLane MF, Kanki PJ: A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science 1985; 230:810-813.
92. Anderson S, Shugars DC, Swanstrom R, Garcia JV: Nef from primary isolates of HIV-1 suppresses surface CD4 expression in human and mouse T cells. J Virol 1993; 67:4923-4931.
93. Garcia JV, Alfano J, Miller D: The negative effect of HIV-1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4. J Virol 1993; 67:1511-1516.
94. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D: Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cyto-plasmic domain. Cell 1994; 76:853-864.
95. Guy B, Kieny MP, Riviere Y, Peuch CL, Dott K, Girard M, Moutagnier L, Lecocq JP: HIV 3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 1987; 330:266-269.
96. Luciw PA, Cheng-Mayer C, Levy JA: Mutational analysis of HIV: the orf-B region downregulates virus replication. Proc Natl Acad Sci USA 1987; 84:1434-1438.
97. Ahmad N, Venkatesan S: Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988; 241:1481-1485.
98. Niederman TM, Thielan BJ, Ratner L: HIV-1 Nef is a transcriptional silencer. Proc Natl Acad Sci USA 1989; 86:1128-1132.
99. Harris M, Coates K: Identification of cellular proteins that bind to the HIV-1 nef gene product in vitro: a role for myristylation. J Gen Virol 1993; 74:1581-1589.
100. Spina CA, Kwoh TJ, Chowers MV, Guatelli JC, Richman D: The importance of nef in the induction of HIV-1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994; 179:115-123.
101. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB: The HIV-1 nef gene product: a possible factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994; 179:101-113.
102. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JB, Gao L, Bloch LM, Chen IS, Zack JA: Requirement of HIV-1 nef for in vivo replication and pathogenicity. J Virol 1994; 68:3478-3485.
103. Arya SK, Guo C, Josephs SF, Wong-Staal F: Trans-activator gene of HTLV-III. Science 1985; 229:69-73.
104. Sodroski J, Patarca R, Rosen C, Wong-Staal F, Haseltine W: Location of the trans-activating region on the genome of HTLV-III. Science 1985; 229:74-77.
105. Aldovini A, Debouck C, Feinberg MB, Rosenberg M, Arya SK, Wong-Staal F: Synthesis of the complete trans-activation gene product of HIV-1 in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro. Proc Natl Acad Sci USA 1986; 83:6672-6676.
106. Frankel AD, Bredt DS, Pabo CO: Tat protein from HIV forms a metal-linked dimer. Science 1988; 240:70-73.
107. Rappaport J, Lee SJ, Khalili K, Wong-Staal F: The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain. New Biol 1989; 1:101-110.
108. Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA, Rosen CA: Structural and functional characterization of HIV Tat protein. J Virol 1989; 63:1-8.
109. Selby MJ, Bain ES, Luciw PA, Peterlin BM: Structure, sequence and position of the stem-loop in TAR determine transcriptional elongation by Tat through the HIV-1 LTR. Genes Dev 1989; 3:547-558.
110. Feng S, Holland EC: HIV-1 Tat transactivation requires the loop sequence within TAR. Nature 1988; 334:165-167.
111. Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N: A bulge structure in HIV-1 TAR is required for Tat binding and Tatmediated activation. Genes Dev 1990; 4:1365-1373.
112. Marciniak RA, Garcia-Blanco MA, Sharp PA: Identification and characterization of a HeLa nuclear protein that specifically binds to the TAR element of HIV. Proc Natl Acad Sci USA 1990; 87:3624-3628.
113. Wu F, Garcia J, Sigman D, Gaynor R: Tat regulates binding of the HIV TAR RNA loop-binding protein TRP-185. Genes Dev 1991; 5:2128-2140.
114. Gatignol A, Buckler-White A, Berkhout B, Jeang KT: Characterization of a human TAR RNA-binding protein that activated the HIV-1 LTR. Science 1991; 251:1597-1600.
115. Rounseville MP, Kumar A: Binding of a host cell nuclear protein to the stem region of HIV-1 TAR RNA. J Virol 1992; 66:1688-1694.
116. Han XM, Laras A, Rounseville MP, Kumar A, Shank PR: HIV-1 Tat-mediated trans-activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor. J Virol 1992; 66:4065-4072.
117. Baker B, Muckenthaler M, Vives E, Blanchard A, Bradock M, Nacken W, Kingsman AJ, Kingsman SM: Identification of a novel HIV-1 TAR RNA bulge binding protein. Nucleic Acids Res 1994; 22:3365-3372.
118. Rice AP: Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the C-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995; 69:1612-1620.
119. Laspia MF, Rice AP, Mathews MB: HIV-1 Tat protein increases transcription initiation and stabilizes elongation. Cell 1989; 59:283-292.
120. Southgate CD, Green MR: The HIV-1 Tat protein activates transcription from an upstream DNA binding site: implication for Tat function. Genes Dev 1991; 5:2496-2507.
121. Cullen BR: Does HIV-1 Tat induce a change in viral initiation rights? Cell 1993; 73:417-420.
122. Jones AK, Peterlin BM: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994; 63:717-743.
123. Bengal E, Aloni Y: Transcriptional elongation by purified RNA polymerase II is blocked at the TAR region of HIV-1 in vitro. J Virol 1991; 65:4910-4918.
124. Marciniak RA, Sharp PA: HIV-1 Tat protein promotes formation of moreprocessive elongation complexes. EMBO J 1991; 10:4189-4196.
125. Kato H, Sumimoto H, Pognonec P, Chen CH, Rosen C, Roeder RG: HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Dev 1992; 6:655-666.
126. Weichs an der Glon CW, Ashe M, Eggermont J, Proudfoot NJ: Tat-dependent occlusion of the HIV poly(A)site. EMBO J 1993; 12:2119-2128.
127. Zhou Q. Sharp PA: Novel mechanism for regulation by HIV-1 Tat. EMBO J 1995; 14:321-328.
128. Bagasra O, Khalili K, Seshamma T, Taylor JP, Pomerantz RJ: TAR-independent replication of HIV-1 in glial cells. J Virol 1992; 66:7522-7528.
129. Taylor JP, Kundu M, Khalili K: TAR-independent activation of HIV-1 requires the activation domain but not the RNA-binding domain of Tat. Virology 1993; 195:780-785.
130. Feinberg MB, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F: HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 1986; 46:807-817.
131. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine W: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986; 322:470-474.
132. Cullen BR, Hauber J, Campbell K., Sodroski JG, Haseltine WA, Rosen CA: Subcellular localization of the HIV trans-acting art gene product. J Virol 1988; 62:2498-2501.
133. Olsen HS, Cochrane AW, Dillon PJ, Nalin CM, Rosen CA: Interaction of HIV-1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev 1990; 4:1357-1364.
134. Malim MH, Cullen BR: HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991; 65:241-248.
135. Zapp ML, Hope TJ, Parslow TG, Green MR: Oligomerization and RNA binding domains of the HIV-1 Rev protein: a dual function for an Arg-rich binding motif. Proc Natl Acad Sci USA 1991; 88:7734-7738.
136. Fischer U, Huber J, Boelens WC, Mattaj IW. Luhrmann R: The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82:475-483.
137. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR: HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990; 60:675-683.
138. Madore SJ, Tiley LS, Malim MH, Cullen BR: Sequence requirements for Rev multimerization in vivo. Virology 1994; 202:186-194.
139. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haseltine WA: Intragenic cis-acting art gene-responsive sequence of the HIV. Proc Natl Acad Sci USA 1988; 85:2071-2075.
140. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR: The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338:254-257.
141. Olsen HS, Nelbock P, Cochrane AW, Rosen CA: Secondary structure is the major determinant for interaction of HIV Rev protein with RNA. Science 1990; 247:845-848.
142. Malim MH, Hauber J, Fenrick R, Cullen BR: Immunodeficiency virus Rev transactivator modulates the expression of the viral regulatory genes. Nature 1988; 335:181-183.
143. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN: Rev protein of HIV-1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci USA 1989; 86:1495-1499.
144. Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN: Mutational inactivation of an inhibitory sequence in HIV-1 results in Rev-independent gag gene expression. J Virol 1992; 66:7176-7182.
145. Cochrane AW, Jones KS, Beidas S, Dillon PJ, Skalka AM, Rosen CA: Identification and characterization of intragenic sequences which repress HIV structural gene expression. J Virol 1991; 65:5305-5313.
146. Schwartz S, Felber BK, Pavlakis GN: Distinct RNA sequences in the gag region of HIV-1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66:150-159.
147. Olsen HS, Cochrane AW, Rosen C: Interaction of cellular factors with intragenic CRSs within the HIV genome. Virology 1992; 191:709-715.
148. Pomerantz RJ, Seshamma T, Trono D: Efficient replication of HIV-1 requires a threshold level of Rev: potential implications for latency. J Virol 1992; 66:1809-1813.
149. Chang DD, Sharp PA: Regulation of HIV Rev depends upon recognition of splice sites. Cell 1989; 59:789-795.
150. Kjems J, Frankel AD, Sharp PS: Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell 1991; 57:169-178.
151. Kjems J, Sharp PA: The basic domain of Rev from HIV-1 specifically blocks the entry of U4/U6-U5 small nuclear ribonucleoprotein in spliceosome assembly. J Virol 1993; 67:4769-4776.
152. Hammarskjold ML, Li H, Rekosh D, Prasad S: HIV Env expression becomes Revindependent if the Env region is not defined as an intron. J Virol 1993; 88:951-958.
153. Stutz F, Rosbash M: A functional interaction between Rev and yeast premRNA is related to splicing complex formation. EMBO J 1994; 13:4096-4104.
154. Fischer U, Meyer S, Teufel M, Heckel C, Luhrmann R, Rautmann G: Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. EMBO J1994; 13:4105-4112.
155. Meyer BE, Malim MH: The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev 1994; 8:1538-1547.
156. D'Agostino DM, Felber BK, Harrison JE, Pavlakis GN: The Rev protein of HIV-1 promotes polysomal association and translation of gag/pol and vpu/ env mRNAs. Mol Cell Biol 1992; 12:1375-1386.
157. Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, Wolff B, Aschauer H, Farrington GK, Probst H, Bevec D, et al: Eukaryotic initiation factor 5A is a cellular target of the HIV-1 Rev activation domain mediating trans-activation. J Cell Biol 1993; 123:1309-1320.
158. Arrigo SJ, Chen ISY: Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 mRNAs. Genes Dev 1991; 5:808-819.
159. Campbell LH, Borg KT, Haines JK, Moon RT., Schoenberg DR, Arrigo SJ: HIV-1 Rev is required in vivo for bin-ding of poly (A)-binding protein to Rev-dependent RNAs. J Virol 1994; 68:5433-5438.
160. Benko DM, Schwartz S, Pavlakis GN, Felber BK: A novel HIV-1 protein, Tev, shares sequences with Tat, Env, and Rev proteins. J Virol 1991; 64:2505-2518.
161. Salfeld J, Gottlinger HG, Sia RA, Park RE, Sodroski JG, Haseltine WA: A tripartite HIV-1 Tat-Env-Rev fusion protein. EMBO J 1990; 9:965-970.
162. Kan NC, Franchini G, Wong-Staal F, DuBois GC, Robey WG, Lautenberger JA, Papas TS: Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science 1986; 231:1553-1555.
163. Goncalves J, Jallepalli P, Gabuzda DH: Subcellular localization of the Vif protein of HIV-1. J Virol 1994; 68:704-712.
164. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F: The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987; 237:888-893.
165. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA: The HIV "A" (sor) gene product is essential for virus infectivity. Nature 1987; 328:728-730.
166. Kishi M, Nishino Y, Sumiya M, Ohki K, Kimura T, Goto T, Nakai M, Kakinuma M, Ikuta K: Cells surviving infection by HIV-1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. J Gen Virol 1992; 73:77-87.
167. Hoglund S, Ohagen A, Lawrence K, Gabuzda D: Role of Vif during packaging of the core of HIV-1. Virology 1994; 201:349-355.
168. - HIV-1. J Virol 1993; 67;6322-6.
169. Von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for HIV-1 proviral DNA synthesis in infected cells. J Virol 1993; 67:4945-4955.
170. Gabuzda H, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E: (1994): Essential role of Vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages J AIDS 1994; 7:908-915.
171. Cohen EA, Terwilliger EF, Jalinoos Y, Proulx J, Sodroski JG, Haseltine WA, Identification of HIV-1 vpr product and function. J AIDS 1990; 3:11-18.
172. Lu YL, Spearman P, Ratner L: HIV-1 Vpr localization in infected cells and virions. J Virol 1993; 67:6542-6550.
173. Paxton W, Connor RI, Landau NR: Incorporation of Vpr into HIV-1 virions: requirement for the p6 region of Gag and mutational analysis. J Virol 1993; 67:7229-7237.
174. gag precursor for incorporation of the vpr product into HIV-1 viral particles. J Virol 1994; 68:1926-1934.
175. Westervelt P, Henkel T, Trowbridge DB, Orenstein J, Heuser J, Gendelman HE, Ratner L: Dual regulation of silent and productive infection in monocytes by distinct HIV-1 determinants. J Virol 1992; 66:3925-3931.
176. Balotta C, Lusso P, Crowley R, Gallo RC, Franchini G: Antisense phosphorotioate oligodeoxynucleotides targeted to the vpr gene inhibit HIV-1 replication in primary human macrophages. J Virol 1993 67:4409-4414.
177. Zhao LJ, Mukherjee S, Narayan O: Biochemical mechanism of HIV-1 Vpr function: specific interaction with a cellular protein. J Biol Chem 1994; 269:15577-15582.
178. Strebel K, Klimkait T, Martin MA: A novel gene of HIV-1, vpu, and its 16-kDa product. Science 1988: 241:1221-1223.
179. Strebel K, Klimkait T, Maldarelli F, Martin MA: Molecular and biochemical analyses of HIV-1 Vpu protein. J Virol 1989; 63: 3784-3791.
180. Maldarelli F, Chen M-Y, Willey RL, Strebel K: HIV-1 Vpu protein is an oligomeric type 1 integral membrane protein. J Virol 1992; 67:5056-5061.
181. Henklein P: et al. Synthesis and characterization of the hydrophilic C-terminal domain of the HIV-1-encoded Vpu. Peptide Res 1993; 6:79-87.
182. Willey RL, Maldarelli F, Martin MA, Strebel K: HIV-1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol 1992; 66:226-234.
183. Willey RL, Maldarelli F, Martin MA, Strebel K: HIV-1 Vpu protein induces rapid degradation of CD4. J Virol 66:7193-7200.
184. Lenburg ME, Landau NR: Vpu-induced degradation of CD4: Requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol 1993; 67:7238-7245.
185. Willey RL, Buckler-White A, Strebel K: Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to HIV-1 Vpu protein. J Virol 1994; 68:1207-1212.
186. Bour S, Schubert U, Strebel K: The HIV-1Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 1995; 69:1510-1520.
187. Schubert U, Strebel K: Differential activities of the HIV-1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 1994; 68:2260-2271.
188. Yao XJ, Garzon S, Boisvert F, Haseltine WA, Cohen EA: The effect of vpu on HIV-1-induced syncytia formation. J AIDS 1993; 6:135-141.
189. Terwilliger EF, Cohen EA, Lu Y, Sodroski JG, Haseltine WA: Functional role of HIV-1 vpu. Proc Natl Acad Sci USA 1989; 86:5163-5167.
190. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM: HIV-1 specific protein vpu is required for efficient virus maturation and release. J Virol 1990; 64:621-629.
191. Yao XJ, Gottlinger H, Haseltine WA, Cohen EA: Env glycoprotein and CD4 independence of vpu facilitated HIV-1 capsid export. J Virol 1992; 66:5119-5126.
192. Gottlinger HG, Dorfman T, Cohen E, Haseltine WA: Vpu protein of HIV-1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 1993; 90:7381-7385.
193. - and an Env glycoprotein-independent function. J Virol 1993,-67:4190-4194.
194. Schwartz S, Felber BK, Pavlakis GN: Mechanism of translation of monocistronic and multicistronic HIV-1 mRNAs. Mol Cell Biol 1992; 12:207-219.
195. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, Gallo RC, Fischinger PJ: Characterization of Env and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985; 228:593-595.
196. Kozarsky K, Penman M, Basiripour L, Haseltine W, Sodroski J, Krieger M: Glycosylation and processing of HIV-1 Env protein. J AIDS 1989; 2:163-169.
197. Stein BS, Engleman EG: Intracellular processing of the gp 160 HTV-1 Env precursor: endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. J Biol Chem 1990; 265:2640-2649.
198. Freed EO, Myers DJ, Risser RJ: Mutational analysis of the cleavage sequence of the HIV-1 Env glycoprotein precursor gp160. J Virol 1989; 63:4670-4675.
199. Fenouillet EJ, Gluckman J: Immunological analysis of HIV-1 Env glycoprotein proteolytic cleavage. Virology 1992; 187:825-828.
200. Dedera D, Gu R, Ratner L: Conserved cysteine residues in the HIV-1 transmembrane Env protein are essential for precursor Env cleavage. J Virol 1992; 66:1207-1209.
201. Owens RJ, Burke C, Rose JK: Mutations in the membrane-spanning domain of the HIV Env glycoprotein that affect fusion activity. J Virol 1994; 68:570-574.
202. Earl PB, Moss B: Mutational analysis of the assembly domain of the HIV-1 Env glycoprotein. AIDS Res Hum Retroviruses 1993; 9:589-594.
203. gag synthesized in yeast is myristylated and targeted to the plasma membrane. Gene 1989; 79:71-81.
204. Bryant M, Ratner L: Myristylation-dependent replication and assembly of HIV-1. Proc Natl Acad Sci USA 1990; 87:523-527.
205. Peng C, Ho BK, Chang TW, Chang NT: Role of HIV-1 specific PR in core protein maturation and viral infectivity. J Virol 1989; 63:2550-2556.
206. Graves MC, Lim JJ, Heimer EP, Kramer RA: An 11-kDa form of HIV PR expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci USA 1988; 85:2449-2453.
207. Sheng N, Erickson-Viitanen S: Cleavage of p15 protein in vitro by HIV-1 PR is RNA dependent. J Virol 1984; 68:6207-6214.
208. Veronese FD M, Copeland TD, Oroszlan S, Gallo RC, Sarngadharan MG: Biochemical and immunological analysis of HIV gag gene products p17 and p24. J Virol 1988; 62:795-801.
209. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE: Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331:280-283.
210. Wilson W, Braddock M, Adams SE, Rathjen PD, Kingsman SM, Kingsman AJ: HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell 1988; 55:1159-1169.
211. Cassan M, Delaunay N, Vaquero C, Rousset JP: Translational frameshifting at the Gag-Pol junction of HIV-1 is not increased in infected T-lymphoid cells J Virol 1994; 68:1501-1508.
212. Le SY, Shapiro BA, Chen JH, Nussinow R, Maizel JV: RNA pseudoknots downstream of the frameshift sites of retroviruses. Genet Anal Tech Appl 1991; 8:191-205.
213. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B: Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 PR and inhibition of assembly and budding of virus-like particles. Virology 1993; 193:661-671.
214. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, Rosenberg M: HIV PR expressed in Escherichia coli is sufficient for enzymatic activity. Proc Natl Acad Sci USA 1987; 84:8903-8906.
215. Vaishnav YN, Wong-Staal F: The biochemistry of AIDS. Annu Rev Biochem: 1991; 60:577-630.
216. Tarrago-Litvak L, Andreola ML, Nevinsky GA, Sarih-Cottin L, Litvak S: The RT of HIV-1: from enzymology to therapeutic intervention. FASEB J 1994; 8:497-503.
217. Lever A, Gottinger H, Haseltine WA, Sodroski JG: Identification of a sequence required for efficient packaging of HIV-1 RNA into virions. J Virol 1989; 63:4085-4087.
218. Aldovini A, Young RA: Mutations of RNA and protein sequences involved in HIV-1 packaging result in production of non-infectious virus. J Virol 1990; 64:1920-1926.
219. Hayashi T, Shioda T, Iwakura Y, Shibuta H: RNA ψ signal of HIV-1. Virology 1992; 188:590-599.
220. Hayashi T, Ueno Y, Okamoto T: Elucidation of a conserved RNA stem-loop structure in the ψ signal of HIV-1. FEBS Lett 1993; 327:213-218.
221. Luban J, Goff S: Mutational analysis of cis-acting signals ψ in HIV-1. J Virol 1994; 68:3784-4793.
222. Clever J, Sassetti C, Parslow TG: RNA secondary structure and binding sites for gag gene products in the 5′ ψ signal of HIV-1. J Virol 1995; 69:2101-2109.
223. Richardson JH, Child LA: Lever AM Packaging of HIV-1 RNA requires cis-acting sequences outside the 5′ leader region. J Virol 1993; 67:3997-4005.
224. Darlix JL, Gabus C, Nugeyre MT, Clavel F, Barre-Sinoussi F: Cis elements and trans-acting factors involved in the RNA dimerization of the HIV-1. J Mol Biol 1990; 216:689-699.
225. Awang G, Sen D: Mode of dimerization of HIV-1 genomic RNA. Biochemistry 1993; 32:11453-11457.
226. Sundquist WI, Heaphy S: Evidence for interstrand quadruplex formation in the dimerization of HIV-1 genomic RNA. Proc Natl Acad Sci USA 1993; 90:3393-3397.
227. Skripkin E, Paillart JC, Marquet R, Ehresmann B, Ehresmann C: Identification of the primary site of the HIV-1 RNA dimerization in vitro. Proc Natl Acad Sci USA 1994; 91:4945-4949.
228. Paillart JC, Marquet R, Skripkin E, Ehresmann B, Ehresmann C: Mutational analysis of the bipartite DLS of HIV-1 genomic RNA. J Biol Chem 1994; 269:27486-27493.
229. Dannull J, Surovoy A, Jung G, Moelling K: Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J 1994; 13: 1525-1533.
230. Lys with NC protein and RT. J Mol Biol 1982; 23:185-190.
231. Jiang M, Mak J, Huang Y, Kleiman L: RT is an important factor for the primer tRNA selection in HIV-1. Leukemia 1994; 8:149-151.
232. Lys into HIV-1 particles. J Virol 1994; 68:2065-2072.
233. Bathurst IC, Chester N, Gibson HL, Dennis AF, Steimer KS, Barr PJ: N-Myristylation of HIV type 1 Gag polyprotein precursor in Saccharomyces cerevisiae. J Virol 1989; 63:3176-3179.
234. gag-pol from HIV-1 into virus-like particles. J Virol 1993; 67:2266-2275.
235. Yu X, Yuan X, Matsuda Z, Lee TH, Essex M: The MA protein of HIV-1 is required for incorporation of viral Env protein into mature virions. J Virol 1992; 66:4966-4971.
236. Lodge R, Gottlinger H, Gabuzda D, Cohen E A, Lemay G: The intracytoplasmic domain of gp41 mediates polarized budding of HIV-1 in MDCK cells. J Virol 1994; 68:4857-4861.
237. Bugelski PJ, Maleeff BE, Klinkner AM, Ventre J, Hart TK: Ultrastructural evidence of an interaction between Env and Gag proteins during assembly of HIV-1. AIDS Res Human Retrovir 1995; 11:55-64.
238. gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus-like particles. J Virol 1990; 64:2743-2750.
239. Sadaie MR, Kalyanaraman VS, Mukopadhayaya R, Tschachler E, Gallo RC, Wong-Staal F: Biological characterization of noninfectious HIV-1 particles lacking the Env protein. Virology 1992; 187:604-611.
240. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA: Effect of mutations affecting p6 gag protein on HIV particle release. Proc Natl Acad Sci USA 1991; 88:3195-3199.
241. Hoglund S, Ofverstedt LG, Nilsson A, Lundquist P, Gelderblom H, Ozel M, Skoglund U: Spatial visualization of the maturing HIV-1 core and its linkage to the envelope. AIDS Res Hum Retroviruses 1992; 8:1-7.
242. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RAF, Scolnick EM, Sigal IS: Active HIV PR is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85:4686-4690.
243. Pantaleo G, Graziosi C, Fauci AS: New concepts in the immunopathogenesis of HIV infection. N Engl J. Med 1993; 328:327-335.
244. Fauci AS: Immunopathogenesis of HIV infection. J AIDS 1993; 6:655-662.
245. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, Resnick L, Felsenstein D, Andrew CA, Hirsch MS: N Engl J Med 1985; 313:1493-1497.
246. Goedert JJ, Biggar RJ, Winn DM, Greene MH, Mann DL, Gallo RC: Determinants of retrovirus HTLV-III antibody and immunodeficiency conditions in homosexual men. Lancet 1984; 2:711-715.
247. Walker BC, Cakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsh MS, Schooley RT: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328: 345-348.
248. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
249. McCune JM: HIV-1: the infective process in vivo. Cell 1991; 64:351-363.
250. Lifson JD, Feinberg MB, Reyes GR, Rabin L, Banapour B, Chakrabarti S, Moss B, Wong-staal F, Steimer KS, Engleman EG: Induction of CD4-dependent cell fusion by the HTLV-III/LAV Env glycoprotein. Nature 1986; 323:725-728.
251. Leonard R, Zagury D, Desportes I, Bernard J, Zagury JF, Gallo RC: Cytopathic effect of HIV in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci USA 1988; 85:3570-3574.
252. Koga Y, Nakamura K, Sasaki M, Kimura G, Nomoto K: The difference in gp160 and gp120 of HIV-1 in the induction of CD4 downregulation preceding single-cell killing. Virology 1994; 201:137-141.
253. Gelderblom HR, Reupke H, Pauli G: Loss of Env antigens of HTLV-IIIILAV, a factor in AIDS pathogenesis? Lancet 1985; 2:1016-1017.
254. Weinhold KJ, Lyerly HK, Stanly SD, Austin AA, Matthews TJ, Bolognesi DP: HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1982; 142:3091-3097.
255. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S: T cell can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 1988; 334:530-532.
256. + cells. J Immunol 1990; 144:2992-2998.
257. Takahashi H, Nakagawa Y, Pendleton CD, Houghten RA, Yokomuro K, Germain RN, Berzofsky JA: Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 Env determinant. Science 1992; 255:333-336.
258. Zinkernagel RM, Hengatner H: T-cell-mediated immunopathology versus direct cytolysis by virus: implication for HIV and AIDS. Immunol Today 1994; 15:262-268.
259. Laurent-Crawford AG, Krust B, Muller S, Riviere Y, Rey-Cuille MA, Bechet JM, Montagnier L, Hovanessan AG: The cytopathic effect of HIV is associated with apoptosis. Virology 1991; 185:829-839.
260. Ameisen JC, Capron A: Cell dysfunction and the depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991; 12:102-105.
261. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D: Selective depletion in HIV infection of T cells that bear specific T cell receptor Vb sequences. Science 1991; 254:860-862.
262. Johnson HM, Russell JK, Pontzer CH: Superantigens in human disease. Scient American April 1992, 92-101.
263. Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Dunlop N, Scandella CJ, Eichberg JW, Steimer KS: Native but not denatured recombinant HIV-1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992; 66:172-182.
264. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB: Neuronal cell killing by the Env protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988; 335:639-642.
265. Lamarre D, Ashkenazi A, Fleury S, Smith DH, Sekaly RP, Capon DJ: The MHC-binding and gp120-binding functions of CD4 are separable. Science 1989; 245:743-746.
266. Rosenstein Y, Burakoff SJ, Herrmann SH: HIV-gp120 can block CD4-class II MHC-mediated adhesion. J Immunol 1990; 144:526-531.
267. Manca F, Habeshaw JA, Dalgleish AG: HIV Env glycoprotein, antigen-specific T cell responses, and soluble CD4. Lancet 1990; 1:811-815.
268. + T cell activation and adhesion by peptides derived from the gp160. J Immunol 1991; 147:475-482.
269. Horak ID, Popovic M, Horak EM, Lucas PJ, Gress RE, June CH, Bolen JB: No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120. Nature 1990; 348:557-560.
270. - cell lines. J Virol 1990; 64:4661-4671.
271. Levy DN, Fernandes LS, Williams WV, Weiner DB: Induction of cell differentiation by HTV-1 Vpr. Cell 1993; 72:541-550.
272. Calenda V, Graber P, Delamarter J-F, Chermann, J-C: Involvement of HIV Nef protein in abnormal hematopoiesis in AIDS: in vitro study on bone marrow progenitor cells. Eur J Haematol 1994; 52:103-107.
273. Shiramizu B, Herndier BG, McGrath MS: Identification of a common clonal HIV integration site in HIV-associated lymphomas. Cancer Res 1994; 54:2069-2072.
274. Haseltine WA: Development of anti-viral drugs for the treatment of AIDS: strategies and prospects. J AIDS 1989; 2:311-334.
275. Johnson VA: Nucleoside RT inhibitors and resistance of HIV-1. J Infect Dis 1995; 171:140-149.
276. Debyser Z, Pauwels R, Andries K, Desmyter J, Kukla M, Janssen PAJ, DeClercq E: An antiviral target on RT of HIV-1 revealed by tetrahydroimidazo[5,1-jk][1,4)-benzodiazepin-2(1H)-one and -thione derivatives. Proc Natl Acad Sci USA 1991; 88:1451-1455.
277. Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ: Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991; 254:1799-1802.
278. Rosen CA: HIV regulatory proteins: potential targets for therapeutic intervention. AIDS Res Hum Retioviruses 1992; 8:175-181.
279. Robins T, Plattner J: HIV PR inhibitors: their anti-HIV activity and potential role in treatment. J AIDS 1993; 6:162-170.
280. Kageyama S, Hoekzema DT, Murakawa Y, Kojima E, Shirasaka T, Kempf DJ, Norbeck DW, Erickson J, Mitsuya H: A C2 symmetry-based HIV PR inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res Hum Retroviruses 1994; 10:735-743.
281. Erickson J, Kempf D: Structure-based design of symmetric inhibitors of HIV-1 PR. Arch Virol 1994; 9:19-29.
282. Pomerantz RJ, Trono D: Genetic therapies for HIV infections: promise for the future. AIDS 1995; 9:985-993.
283. Medina MF, Ramezani A, Joshi S: Anti-HTV-1 gene therapy. Transfus Sci (in press).
284. Sarver N, Cantin E, Chang P, Ladne P, Stephens D, Zaia J, Rossi J: Ribozyme as potential anti-HIV-1 therapeutic agents. Science 1990; 247:1222-1225.
285. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV RNA specific ribozyme. J Virol 1991; 65:5531-5534.
286. Ramezani R, Joshi S: Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Antisense Nucleic Acid Drug Devel (in press).
287. Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D, Wong-Staal F: A hairpin ribozyme inhibits expression of diverse strains of HIV-1. Proc Natl Acad Sci USA 1993; 90:6340-6344.
288. Zhao C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn EB: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-Tat and Rev hammerhead ribozymes. Gene 1994; 1494:33-39.
289. Yamada O, Kraus G, Leavitt MC, Yu M. Wong-Staal F: Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells. Virology 1994; 205:121-126.
290. Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F: Intracellular immunization of human T-cells with a hairpin ribozyme against HIV-1. Gene Therapy 1994; 1:38-45.
291. Rhodes A, James W: Inhibition of heterologous strain of HIV by antisense RNA. AIDS 1991; 5:145-151.
292. Joshi S, van Brunschot A, Asad S, van der Elst I, Read SE, Bernstein A: Inhibition of HIV-1 multiplication by antisense and sense RNA. J Virol 1991; 65:5524-5530.
293. + lymphoid cell line expressing antisense and sense RNA molecules containing HIV-1 ψ signal and RRE element(s). Antisense Res Dev 1994; 4:19-26.
294. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E: Analysis of TAR decoy RNA-mediated inhibition of HIV-1 transactivation. J Virol 1991; 65:6811-6816.
295. Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, Gallo RC: Inhibition of HIV-1 replication by regulated expression of a polymeric TAR RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993; 90:8000-8004.
296. + T lymphocytes. Hum Gene Ther 1994; 5:193-201.
297. Feinberg MB, Trono D: Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. AIDS Res and Human Retroviruses 1992; 6:1013-1022.
298. Bevec D, Dobrovnik M, Hauber J, Bohnlein E: Inhibition of HIV-1 replication in human T cells by retrovirally mediated gene transfer of a dominantnegative Rev trans-activator. Proc Natl Acad Sci USA 1992; 89:9870-9874.
299. Liem SE, Ramezani A, Li X, Joshi S: The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Human Gene Ther 1993; 4:625-534.
300. Bahner I, Zhou C, Yu XJ, Hao QL, Guatelli JC, Kohn DB: Comparison of trans-dominant inhibitory mutant HTV-1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993; 67:3199-3207.
301. Smythe JA, Sun D, Thomson M, Markham PD, Reitz MS Jr, Gallo RC, Lisziewicz J: A Rev-inducible mutant gag gene stably transformed into T lymphocytes: an approach to gene therapy against HIV-1 infection. Proc Natl Acad Sci USA 1994; 91:3657-3661.
302. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ: Potent inhibition of HIV-1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994; 91:5075-5079.
303. Chen SY, Bagley J, Marasco WA: Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994; 5:595-601.
304. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA: Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995; 14:1542-1551.
305. Harrison GS, Maxwell F, Long C, Rosen CA, Glode M, Maxwell IH: Activation of a diphtheria toxin A gene by expression of HIV-1 Tat and Rev proteins in transfected cells. Hum Gene Ther 1991; 2:53-60.
306. Harrison GS, Long CJ, Maxwell F, Glode LM, Maxwell IH: Inhibition of HIV production in cells containing an integrated, HIV-regulated diphtheria toxin A chain gene. AIDS Res Hum Retroviruses 1992; 8:39-45.
307. + cells harboring a HIV-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci USA 1992; 89:182-186.
308. Curiel TJ, Cook DR, Wang Y, Hahn BH, Ghosh SK, Harrison GS: Long-term inhibition of clinical and laboratory HIV strains in human T-cell lines containing an HIV-regulated diphteria toxin A chain gene. Hum Gene Ther 1993; 5:193-201.
309. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs Jr CJ, Gajdusek DC: HIV-1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988; 85:4478-4482.
310. Redfield RR, Birx DL, Ketter M, Tramont M, Polonis V, Davis C, Brundage JF, Smith GG, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke DS and the Military Medical Consortium for Applied Retroviral Research: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early HIV infection. N Engl J Med 1991; 324:1676-1684.
311. Haffar OK, Moran PA, Smithgall PA, Diegel ML, Sridhar P, Ledbetter JA, Zarling JM, Hu SL: Inhibition of virus production in peripheral blood mononuclear cells from HTV-1 seropositive donors by treatment with recombinant HIV-like particles. J Virol 1992; 66:4279-4287.
312. Rovinski B, Haynes JR, Cao SH, James O, Sia C, Zolla-Panzer S, Matthews TJ, Klein MH: Expression and characterization of genetically engineered HIV like particles containing modified Env glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol 1992; 66:4003-4012.
313. Wigzell H: Prospects for an HIV-vaccine. FASEB J 1991; 5:2406-2411.
314. Desrosiers RC: HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992; 8:411-421.